Markets
Borrow
Earn
Invest
Private
Security
Newsroom
More
Log In
Sign Up
Markets
Market Overview
Indices and commodities.
Digital Credit
Bitcoin treasury preferreds.
AI Stocks
The artificial intelligence theme.
Bitcoin Treasuries
Companies holding bitcoin.
Economy
Sectors, global markets and rates.
Popular Portfolios
13F filings, smart money.
Borrow
Borrow
Borrow USDT or USDC against your BTC without giving it up.
ReFi
Switch your bitcoin-backed loan and pay less interest.
Earn
Carry Trade
Borrow, invest, keep the spread.
Stock Dividends
Dividends from tokenized equities.
Invest
Private
Security
Newsroom
More
Company
About Us
Our leadership team, mission, and investors.
Whitepaper
Vision, purpose, and architecture behind Roxom.
Legal
Terms, privacy, and disclosures.
Resources
Help Center
Guides, FAQs & support.
Rulebook
Trading logic, platform rules, and fundamentals.
API Docs
Connect, authenticate, and build with our API.
Status
Current platform health and incidents.
Chart
Financials
Earnings
News
About
Dividends
Insider
Filings
BTC
SATS
USD
1d
1w
1m
6m
YTD
1y
5y
All
Loading chart
1 BTC
=
- USD
BTC
SATS
Loading market data...
Chart
Financials
Earnings
News
About
Dividends
Insider
Filings
BTC
SATS
USD
1d
1w
1m
6m
YTD
1y
5y
All
Loading chart
IR
Iridex Corp
IRIX
Volume
42.01K
Next Earnings
November 10th
Chart
Financials
Earnings
News
About
Dividends
Insider
Filings
BTC
SATS
USD
1d
1w
1m
6m
YTD
1y
5y
All
Loading chart
IR
IRIX
IR
Iridex Corp
IRIX
News
·
Iridex Announces the Publication of Two-Year Independent Study Supporting Benefits of MicroPulse® Technology for Early to Advanced Glaucoma
Mkt Cap
$14.5M
Volume
42.01K
Next Earnings
November 10th
Chart
Financials
Earnings
News
About
Insider
Filings
Iridex Announces the Publication of Two-Year Independent Study Supporting Benefits of MicroPulse® Technology for Early to Advanced Glaucoma
Iridex Corporation announced the publication of a two-year clinical study in the International Journal of Ophthalmology demonstrating that MicroPulse transscleral laser therapy (TLT) significantly reduces intraocular pressure and medication burden in patients with early to advanced glaucoma. The study of 84 eyes showed mean IOP reduction from 22.32 mmHg to 14.05 mmHg, with 86% success rate in POAG patients and 81% in PACG patients, with no reported complications or visual acuity reductions.
GlobeNewswire Inc. · Oct 12, 2026
Iridex Announces Plans to Relocate Headquarters
Iridex Corporation announced its intent to relocate its headquarters from Mountain View, California to San Jose, California. The company signed a non-binding letter of intent for a 31,000 square feet location on January 26, 2026, expecting to generate approximately $0.4 million in savings for fiscal year 2026 and $0.6 million in annualized savings thereafter. The relocation is part of the company's ongoing cost reduction strategy while maintaining operations and talent attraction in the Bay Area.
GlobeNewswire Inc. · Feb 2, 2026
Iridex Announces the Publication of an Independent Study Demonstrating Safe and Effective Retreatment with Transscleral Laser Treatment Using MicroPulse® Technology in Glaucoma Management
An independent study demonstrated that retreatment with MicroPulse® transscleral laser technology can safely reduce intraocular pressure in glaucoma patients, with IOP reductions ranging from 25% to 35% across different patient groups.
GlobeNewswire Inc. · Dec 11, 2025
Iridex Reports 7 Percent Q2 Revenue Gain
Medical device company Iridex reported Q2 2025 results with modest revenue growth, narrower net loss, and positive adjusted EBITDA, driven by cost control and operational discipline.
The Motley Fool · Aug 13, 2025
Iridex Comments on Recent Stock Price Volatility
Iridex Corporation, a leader in laser-based medical systems for ophthalmology, commented on recent stock price volatility, stating that there have been no material changes to its operating or financial condition.
GlobeNewswire Inc. · Mar 14, 2025
Iridex to Report Fourth Quarter and Full Year 2024 Financial Results on March 27, 2025
Iridex Corporation, a leader in laser-based medical systems for ophthalmology, announces plans to release its Q4 and full-year 2024 financial results and provide a business update on March 27, 2025.
GlobeNewswire Inc. · Mar 13, 2025
Medical Lasers Market Size is Projected to Reach USD 12.02 billion by 2033, Growing at a CAGR of 9.10%: Straits Research
The global medical lasers market is projected to grow from $5.99 billion in 2025 to $12.02 billion by 2033, driven by the increasing demand for non-invasive cosmetic procedures and advancements in medical laser technology.
GlobeNewswire Inc. · Jan 17, 2025
Ophthalmic Lasers Market, Competitive Landscape and Market Forecasts to 2030
The global ophthalmic laser devices market is expected to grow at a CAGR of 6.11% from 2024 to 2030, driven by the rising prevalence of ophthalmic diseases and the increasing preference for minimally invasive procedures. Key players in the market include Alcon, IRIDEX, BAUSCH + LOMB, and Johnson & Johnson Vision.
GlobeNewswire Inc. · Dec 16, 2024
Iridex (IRIX) Reports Q1 Loss, Misses Revenue Estimates
Iridex (IRIX) delivered earnings and revenue surprises of -75% and 1.99%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
Zacks Investment Research · May 14, 2024
Lumentum (LITE) Q3 Earnings Beat Estimates
Lumentum (LITE) delivered earnings and revenue surprises of 11.54% and 0.01%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
Zacks Investment Research · May 6, 2024
Holdings
Open Orders (0)
Positions (0)
Order History
Dividends
Transfers
Log In
to start trading
IR
IRIX
Iridex Corp
Buy
Sell
Market
Limit
Soon
IRIX
25%
50%
75%
Max
Pay with
—
Start Trading
Available Balance
0.00
Your Position
You don't own any IRIX yet.
Related Tickers
Earnings